284 related articles for article (PubMed ID: 35779210)
1. Bone loss induced by cancer treatments in breast and prostate cancer patients.
Castañeda S; Casas A; González-Del-Alba A; Martínez-Díaz-Guerra G; Nogués X; Ojeda Thies C; Torregrosa Suau Ó; Rodríguez-Lescure Á
Clin Transl Oncol; 2022 Nov; 24(11):2090-2106. PubMed ID: 35779210
[TBL] [Abstract][Full Text] [Related]
2. Cancer-treatment-induced bone loss, part 2.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
[TBL] [Abstract][Full Text] [Related]
3. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.
Michaud LB
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 3):S20-30; quiz S31-3. PubMed ID: 20332495
[TBL] [Abstract][Full Text] [Related]
4. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
[TBL] [Abstract][Full Text] [Related]
5. Bone health during endocrine therapy for cancer.
Rachner TD; Coleman R; Hadji P; Hofbauer LC
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
[TBL] [Abstract][Full Text] [Related]
6. Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey.
Valsecchi AA; Fusco V; Di Maio M; Santini D; Tucci M; De Giorgi U; Dionisio R; Vignani F; Cinieri S
Tumori; 2024 Jun; 110(3):174-185. PubMed ID: 38462772
[TBL] [Abstract][Full Text] [Related]
7. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
8. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
Body JJ; Bergmann P; Boonen S; Boutsen Y; Devogelaer JP; Goemaere S; Reginster JY; Rozenberg S; Kaufman JM
Osteoporos Int; 2007 Nov; 18(11):1439-50. PubMed ID: 17690930
[TBL] [Abstract][Full Text] [Related]
9. Early breast and prostate cancer and clinical outcomes (fracture).
Chlebowski RT; Tagawa T
Oncology (Williston Park); 2009 Dec; 23(14 Suppl 5):16-20. PubMed ID: 20128324
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the management of cancer treatment induced bone loss.
Bertoldo F; Pancheri S; Zenari S; Boldini S
Expert Opin Emerg Drugs; 2010 Jun; 15(2):323-42. PubMed ID: 20377485
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation in prostate cancer and the long-term risk of fracture.
Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
[TBL] [Abstract][Full Text] [Related]
12. Antiresorptive therapy in the management of cancer treatment-induced bone loss.
Garg A; Leitzel K; Ali S; Lipton A
Curr Osteoporos Rep; 2015 Apr; 13(2):73-7. PubMed ID: 25575469
[TBL] [Abstract][Full Text] [Related]
13. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis in breast and prostate cancer survivors.
Hoff AO; Gagel RF
Oncology (Williston Park); 2005 Apr; 19(5):651-8. PubMed ID: 15945345
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of bone loss in patients with nonmetastatic breast or prostate cancer who receive hormonal ablation therapy.
Limburg C; Maxwell C; Mautner B
Clin J Oncol Nurs; 2014 Apr; 18(2):223-30. PubMed ID: 24675258
[TBL] [Abstract][Full Text] [Related]
16. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
17. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
18. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Greenspan SL; Nelson JB; Trump DL; Wagner JM; Miller ME; Perera S; Resnick NM
J Clin Oncol; 2008 Sep; 26(27):4426-34. PubMed ID: 18802155
[TBL] [Abstract][Full Text] [Related]
19. Management of bone loss in men with prostate cancer.
Higano CS
J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
[TBL] [Abstract][Full Text] [Related]
20. [Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation].
Morote J; Planas J
Actas Urol Esp; 2011 Apr; 35(4):232-9. PubMed ID: 21419516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
